Stifel Maintains Buy on Definitive Healthcare, Lowers Price Target to $11-Report Released on 16 January 2024
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst David Grossman has maintained a Buy rating on Definitive Healthcare (NASDAQ:DH) but has reduced the price target from $12 to $11 as reported on January 16, 2024.

January 17, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Stifel analyst David Grossman maintains a Buy rating on Definitive Healthcare but lowers the price target from $12 to $11.
While the reduction in price target could suggest a more conservative valuation or perceived lower growth prospects, the maintenance of a Buy rating indicates that the analyst still sees upside potential in the stock. The impact on the stock price is likely to be mixed in the short term, as the market digests both the positive endorsement and the lowered price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100